Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2011

Open Access 01-12-2011 | Research article

A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines

Authors: Christian Freise, Martin Ruehl, Ulrike Erben, Ulf Neumann, Daniel Seehofer, Ki Young Kim, Wolfram Trowitzsch-Kienast, Thorsten Stroh, Martin Zeitz, Rajan Somasundaram

Published in: BMC Complementary Medicine and Therapies | Issue 1/2011

Login to get access

Abstract

Background

In traditional Chinese and Korean medicine, an aqueous extract derived from wood and bark of the Japanese spice bush Lindera obtusiloba (L.obtusiloba) is applied to treat inflammations and chronic liver diseases including hepatocellular carcinoma. We previously demonstrated anti-fibrotic effects of L.obtusiloba extract in hepatic stellate cells. Thus, we here consequently examine anti-neoplastic effects of L.obtusiloba extract on human hepatocellular carcinoma (HCC) cell lines and the signaling pathways involved.

Methods

Four human HCC cell lines representing diverse stages of differentiation were treated with L.obtusiloba extract, standardized according to its known suppressive effects on proliferation and TGF-β-expression. Beside measurement of proliferation, invasion and apoptosis, effects on signal transduction and NF-κB-activity were determined.

Results

L.obtusiloba extract inhibited proliferation and induced apoptosis in all HCC cell lines and provoked a reduced basal and IGF-1-induced activation of the IGF-1R signaling cascade and a reduced transcriptional NF-κB-activity, particularly in the poorly differentiated SK-Hep1 cells. Pointing to anti-angiogenic effects, L.obtusiloba extract attenuated the basal and IGF-1-induced expression of hypoxia inducible factor-1α, vascular endothelial growth factor, peroxisome proliferator-activated receptor-γ, cyclooxygenase-2 and inducible nitric oxide synthase.

Conclusions

The traditional application of the extract is confirmed by our experimental data. Due to its potential to inhibit critical receptor tyrosine kinases involved in HCC progression via the IGF-1 signaling pathway and NF-κB, the standardized L.obtusiloba extract should be further analysed for its active compounds and explored as (complementary) treatment option for HCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007, 132: 2557-2576. 10.1053/j.gastro.2007.04.061.CrossRefPubMed El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007, 132: 2557-2576. 10.1053/j.gastro.2007.04.061.CrossRefPubMed
2.
go back to reference Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007, 27: 55-76. 10.1055/s-2006-960171.CrossRefPubMed Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM: Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis. 2007, 27: 55-76. 10.1055/s-2006-960171.CrossRefPubMed
3.
go back to reference Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10: 25-34. 10.1016/S1470-2045(08)70285-7.CrossRefPubMed Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009, 10: 25-34. 10.1016/S1470-2045(08)70285-7.CrossRefPubMed
4.
go back to reference Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359: 378-390. 10.1056/NEJMoa0708857.CrossRefPubMed Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008, 359: 378-390. 10.1056/NEJMoa0708857.CrossRefPubMed
5.
go back to reference Lasagna N, Fantappie O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R: Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res. 2006, 66: 2673-2682. 10.1158/0008-5472.CAN-05-2290.CrossRefPubMed Lasagna N, Fantappie O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R: Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res. 2006, 66: 2673-2682. 10.1158/0008-5472.CAN-05-2290.CrossRefPubMed
6.
go back to reference Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995, 16: 3-34.PubMed Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995, 16: 3-34.PubMed
7.
go back to reference Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM: Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 2010, 2010: 20- Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM: Cancer gene discovery in hepatocellular carcinoma. J Hepatol. 2010, 2010: 20-
8.
go back to reference Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000, 21: 215-244. 10.1210/er.21.3.215.CrossRefPubMed Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE: The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000, 21: 215-244. 10.1210/er.21.3.215.CrossRefPubMed
9.
go back to reference Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004, 4: 505-518. 10.1038/nrc1387.CrossRefPubMed Pollak MN, Schernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004, 4: 505-518. 10.1038/nrc1387.CrossRefPubMed
10.
go back to reference Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A: An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol. 2004, 68: 1003-1015. 10.1016/j.bcp.2004.05.029.CrossRefPubMed Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G, Groyer A: An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol. 2004, 68: 1003-1015. 10.1016/j.bcp.2004.05.029.CrossRefPubMed
11.
go back to reference Parrizas M, Saltiel AR, LeRoith D: Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways. J Biol Chem. 1997, 272: 154-161. 10.1074/jbc.272.1.154.CrossRefPubMed Parrizas M, Saltiel AR, LeRoith D: Insulin-like growth factor 1 inhibits apoptosis using the phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways. J Biol Chem. 1997, 272: 154-161. 10.1074/jbc.272.1.154.CrossRefPubMed
12.
go back to reference Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R: Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol. 1999, 19: 7203-7215.CrossRefPubMedPubMedCentral Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga R: Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol. 1999, 19: 7203-7215.CrossRefPubMedPubMedCentral
13.
go back to reference Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL: Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002, 277: 38205-38211. 10.1074/jbc.M203781200. Epub 32002 Jul 38230CrossRefPubMed Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL: Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 2002, 277: 38205-38211. 10.1074/jbc.M203781200. Epub 32002 Jul 38230CrossRefPubMed
14.
go back to reference Nakamura K, Zen Y, Sato Y, Kozaka K, Matsui O, Harada K, Nakanuma Y: Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1alpha are involved in malignant transformation in dysplastic nodules of the liver. Hum Pathol. 2007, 38: 1532-1546. 10.1016/j.humpath.2007.03.002. Epub 2007 Jul 1519CrossRefPubMed Nakamura K, Zen Y, Sato Y, Kozaka K, Matsui O, Harada K, Nakanuma Y: Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1alpha are involved in malignant transformation in dysplastic nodules of the liver. Hum Pathol. 2007, 38: 1532-1546. 10.1016/j.humpath.2007.03.002. Epub 2007 Jul 1519CrossRefPubMed
15.
go back to reference Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, Hashimoto O, Sugawara H, Tanikawa K: Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol. 1998, 29: 986-991. 10.1016/S0046-8177(98)90205-2.CrossRefPubMed Torimura T, Sata M, Ueno T, Kin M, Tsuji R, Suzaku K, Hashimoto O, Sugawara H, Tanikawa K: Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol. 1998, 29: 986-991. 10.1016/S0046-8177(98)90205-2.CrossRefPubMed
16.
go back to reference Samani AA, Yakar S, LeRoith D, Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007, 28: 20-47. Epub 2006 Aug 2024CrossRefPubMed Samani AA, Yakar S, LeRoith D, Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev. 2007, 28: 20-47. Epub 2006 Aug 2024CrossRefPubMed
17.
go back to reference De Meyts P, Whittaker J: Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov. 2002, 1: 769-783. 10.1038/nrd917.CrossRefPubMed De Meyts P, Whittaker J: Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov. 2002, 1: 769-783. 10.1038/nrd917.CrossRefPubMed
18.
go back to reference Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Sole M, Thung S, Moyano S, Toffanin S, Minguez B, et al: IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J. 2010, 52: 550-559. Tovar V, Alsinet C, Villanueva A, Hoshida Y, Chiang DY, Sole M, Thung S, Moyano S, Toffanin S, Minguez B, et al: IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J. 2010, 52: 550-559.
19.
go back to reference Higano C, Yu E, Whiting S, Gordon M, LoRusso P, Fox F: A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor 1 receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol. 2007, 25 (Suppl 18): 3505-[abstract] Higano C, Yu E, Whiting S, Gordon M, LoRusso P, Fox F: A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor 1 receptor IgG1 monoclonal antibody, in patients with advanced solid tumors. J Clin Oncol. 2007, 25 (Suppl 18): 3505-[abstract]
20.
go back to reference Salminen A, Kaarniranta K: Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-kappaB signaling. Cell Signal. 2010, 22: 573-577. 10.1016/j.cellsig.2009.10.006.CrossRefPubMed Salminen A, Kaarniranta K: Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-kappaB signaling. Cell Signal. 2010, 22: 573-577. 10.1016/j.cellsig.2009.10.006.CrossRefPubMed
21.
go back to reference Naugler WE, Karin M: NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008, 18: 19-26. 10.1016/j.gde.2008.01.020. Epub 2008 Apr 2024CrossRefPubMedPubMedCentral Naugler WE, Karin M: NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev. 2008, 18: 19-26. 10.1016/j.gde.2008.01.020. Epub 2008 Apr 2024CrossRefPubMedPubMedCentral
22.
go back to reference Liu TZ, Hu CC, Chen YH, Stern A, Cheng JT: Differentiation status modulates transcription factor NF-kappaB activity in unstimulated human hepatocellular carcinoma cell lines. Cancer Lett. 2000, 151: 49-56. 10.1016/S0304-3835(99)00404-8.CrossRefPubMed Liu TZ, Hu CC, Chen YH, Stern A, Cheng JT: Differentiation status modulates transcription factor NF-kappaB activity in unstimulated human hepatocellular carcinoma cell lines. Cancer Lett. 2000, 151: 49-56. 10.1016/S0304-3835(99)00404-8.CrossRefPubMed
23.
go back to reference Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S: Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res. 2005, 11: 7674-7682. 10.1158/1078-0432.CCR-05-1205.CrossRefPubMed Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S: Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res. 2005, 11: 7674-7682. 10.1158/1078-0432.CCR-05-1205.CrossRefPubMed
24.
go back to reference Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, Frau M, Tomasi ML, De Miglio MR, Seddaiu MA, et al: Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis. 2008, 29: 1639-1647. 10.1093/carcin/bgn155. Epub 2008 Jun 1625CrossRefPubMed Calvisi DF, Pinna F, Ladu S, Pellegrino R, Muroni MR, Simile MM, Frau M, Tomasi ML, De Miglio MR, Seddaiu MA, et al: Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis. 2008, 29: 1639-1647. 10.1093/carcin/bgn155. Epub 2008 Jun 1625CrossRefPubMed
25.
go back to reference Khan N, Mukhtar H: Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett. 2008, 269: 269-280. 10.1016/j.canlet.2008.04.014. Epub 2008 May 2022CrossRefPubMedPubMedCentral Khan N, Mukhtar H: Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett. 2008, 269: 269-280. 10.1016/j.canlet.2008.04.014. Epub 2008 May 2022CrossRefPubMedPubMedCentral
26.
go back to reference Stickel F, Brinkhaus B, Krahmer N, Seitz HK, Hahn EG, Schuppan D: Antifibrotic properties of botanicals in chronic liver disease. Hepatogastroenterology. 2002, 49: 1102-1108.PubMed Stickel F, Brinkhaus B, Krahmer N, Seitz HK, Hahn EG, Schuppan D: Antifibrotic properties of botanicals in chronic liver disease. Hepatogastroenterology. 2002, 49: 1102-1108.PubMed
27.
go back to reference Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH: Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the NF-{kappa}B signal. Mol Pharmacol. 2009, 14: 14- Lee JH, Jin H, Shim HE, Kim HN, Ha H, Lee ZH: Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the NF-{kappa}B signal. Mol Pharmacol. 2009, 14: 14-
28.
go back to reference Yook C: Lindera obtusiloba. Medical Plants of Korea. 1989, Seoul: Jinmyeong Publishing Co., 184- Yook C: Lindera obtusiloba. Medical Plants of Korea. 1989, Seoul: Jinmyeong Publishing Co., 184-
29.
go back to reference Kwon HC, Baek NI, Choi SU, Lee KR: New cytotoxic butanolides from Lindera obtusiloba BLUME. Chem Pharm Bull (Tokyo). 2000, 48: 614-616.CrossRef Kwon HC, Baek NI, Choi SU, Lee KR: New cytotoxic butanolides from Lindera obtusiloba BLUME. Chem Pharm Bull (Tokyo). 2000, 48: 614-616.CrossRef
30.
go back to reference Kwon HC, Choi SU, Lee JO, Bae KH, Zee OP, Lee KR: Two new lignans from Lindera obtusiloba blume. Arch Pharm Res. 1999, 22: 417-422. 10.1007/BF02979069.CrossRefPubMed Kwon HC, Choi SU, Lee JO, Bae KH, Zee OP, Lee KR: Two new lignans from Lindera obtusiloba blume. Arch Pharm Res. 1999, 22: 417-422. 10.1007/BF02979069.CrossRefPubMed
31.
go back to reference Ruehl M, Erben U, Kim K, Freise C, Dagdelen T, Eisele S, Trowitzsch-Kienast W, Zeitz M, Jia J, Stickel F, Somasundaram R: Extracts of Lindera obtusiloba induce antifibrotic effects in hepatic stellate cells via suppression of a TGF-beta-mediated profibrotic gene expression pattern. J Nutr Biochem. 2009, 20: 597-606. 10.1016/j.jnutbio.2008.06.003. Epub 2008 Sep 2027CrossRefPubMed Ruehl M, Erben U, Kim K, Freise C, Dagdelen T, Eisele S, Trowitzsch-Kienast W, Zeitz M, Jia J, Stickel F, Somasundaram R: Extracts of Lindera obtusiloba induce antifibrotic effects in hepatic stellate cells via suppression of a TGF-beta-mediated profibrotic gene expression pattern. J Nutr Biochem. 2009, 20: 597-606. 10.1016/j.jnutbio.2008.06.003. Epub 2008 Sep 2027CrossRefPubMed
32.
go back to reference Freise C, Erben U, Kim K, Zeitz M, Somasundaram R, Ruehl M: An active extract of Lindera obtusiloba inhibits adipogenesis via sustained Wnt signaling and exerts anti inflammatory effects in the 3T3-L1 preadipocytes. J Nutr Biochem. 2010, 12: 1170-1177. doi:10.1016/j.jnutbio.2009.09.013. Epub 2010 Jan 25CrossRef Freise C, Erben U, Kim K, Zeitz M, Somasundaram R, Ruehl M: An active extract of Lindera obtusiloba inhibits adipogenesis via sustained Wnt signaling and exerts anti inflammatory effects in the 3T3-L1 preadipocytes. J Nutr Biochem. 2010, 12: 1170-1177. doi:10.1016/j.jnutbio.2009.09.013. Epub 2010 Jan 25CrossRef
33.
go back to reference Stroh T, Batra A, Glauben R, Fedke I, Erben U, Kroesen A, Heimesaat MM, Bereswill S, Girardin S, Zeitz M, Siegmund B: Nucleotide oligomerization domains 1 and 2: regulation of expression and function in preadipocytes. J Immunol. 2008, 181: 3620-3627.CrossRefPubMed Stroh T, Batra A, Glauben R, Fedke I, Erben U, Kroesen A, Heimesaat MM, Bereswill S, Girardin S, Zeitz M, Siegmund B: Nucleotide oligomerization domains 1 and 2: regulation of expression and function in preadipocytes. J Immunol. 2008, 181: 3620-3627.CrossRefPubMed
34.
go back to reference Stroh T, Erben U, Kuhl AA, Zeitz M, Siegmund B: Combined pulse electroporation--a novel strategy for highly efficient transfection of human and mouse cells. PLoS. 2010, 5: e9488-CrossRef Stroh T, Erben U, Kuhl AA, Zeitz M, Siegmund B: Combined pulse electroporation--a novel strategy for highly efficient transfection of human and mouse cells. PLoS. 2010, 5: e9488-CrossRef
35.
go back to reference Okun I, Balakin KV, Tkachenko SE, Ivachtchenko AV: Caspase activity modulators as anticancer agents. Anticancer Agents Med Chem. 2008, 8: 322-341. 10.2174/187152008783961914.CrossRefPubMed Okun I, Balakin KV, Tkachenko SE, Ivachtchenko AV: Caspase activity modulators as anticancer agents. Anticancer Agents Med Chem. 2008, 8: 322-341. 10.2174/187152008783961914.CrossRefPubMed
36.
go back to reference Kaur G, Hollingshead M, Holbeck S, Schauer-Vukasinovic V, Camalier RF, Domling A, Agarwal S: Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. Biochem J. 2006, 396: 235-242. 10.1042/BJ20051735.CrossRefPubMedPubMedCentral Kaur G, Hollingshead M, Holbeck S, Schauer-Vukasinovic V, Camalier RF, Domling A, Agarwal S: Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product. Biochem J. 2006, 396: 235-242. 10.1042/BJ20051735.CrossRefPubMedPubMedCentral
37.
go back to reference Greten TF, Korangy F, Manns MP, Malek NP: Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer. 2009, 100: 19-23. 10.1038/sj.bjc.6604784. Epub 2008 Nov 2018CrossRefPubMed Greten TF, Korangy F, Manns MP, Malek NP: Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer. 2009, 100: 19-23. 10.1038/sj.bjc.6604784. Epub 2008 Nov 2018CrossRefPubMed
38.
go back to reference Shimizu M, Shirakami Y, Sakai H, Tatebe H, Nakagawa T, Hara Y, Weinstein IB, Moriwaki H: EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett. 2007, 28: 28- Shimizu M, Shirakami Y, Sakai H, Tatebe H, Nakagawa T, Hara Y, Weinstein IB, Moriwaki H: EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett. 2007, 28: 28-
39.
go back to reference Pang R, Poon RT: Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006, 242: 151-167. 10.1016/j.canlet.2006.01.008. Epub 2006 Mar 2027CrossRefPubMed Pang R, Poon RT: Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 2006, 242: 151-167. 10.1016/j.canlet.2006.01.008. Epub 2006 Mar 2027CrossRefPubMed
40.
go back to reference Mitsiades CS, Mitsiades N, Koutsilieris M: The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets. 2004, 4: 235-256. 10.2174/1568009043333032.CrossRefPubMed Mitsiades CS, Mitsiades N, Koutsilieris M: The Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets. 2004, 4: 235-256. 10.2174/1568009043333032.CrossRefPubMed
41.
go back to reference Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, et al: Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005, 24: 5552-5560. 10.1038/sj.onc.1208719.CrossRefPubMed Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, et al: Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005, 24: 5552-5560. 10.1038/sj.onc.1208719.CrossRefPubMed
42.
go back to reference Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD: Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther. 2006, 5: 1227-1238. 10.1158/1535-7163.MCT-05-0490.CrossRefPubMed Zhang Q, Tang X, Lu Q, Zhang Z, Rao J, Le AD: Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther. 2006, 5: 1227-1238. 10.1158/1535-7163.MCT-05-0490.CrossRefPubMed
43.
go back to reference Borbath I, Horsmans Y: The Role of PPARγ in Hepatocellular Carcinoma. PPAR Research. 2008 Borbath I, Horsmans Y: The Role of PPARγ in Hepatocellular Carcinoma. PPAR Research. 2008
44.
go back to reference Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N: Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res. 2001, 7: 1325-1332.PubMed Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N: Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res. 2001, 7: 1325-1332.PubMed
45.
go back to reference Wu T: Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev. 2006, 32: 28-44. 10.1016/j.ctrv.2005.10.004. Epub 2005 Dec 2007CrossRefPubMed Wu T: Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev. 2006, 32: 28-44. 10.1016/j.ctrv.2005.10.004. Epub 2005 Dec 2007CrossRefPubMed
46.
go back to reference Hussain SP, Harris CC: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007, 121: 2373-2380. 10.1002/ijc.23173.CrossRefPubMed Hussain SP, Harris CC: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007, 121: 2373-2380. 10.1002/ijc.23173.CrossRefPubMed
47.
go back to reference Nagahara T, Okano J, Murawaki Y: Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells. Oncol Rep. 2007, 18: 1281-1290.PubMed Nagahara T, Okano J, Murawaki Y: Mechanisms of anti-proliferative effect of JTE-522, a selective cyclooxygenase-2 inhibitor, on human liver cancer cells. Oncol Rep. 2007, 18: 1281-1290.PubMed
48.
go back to reference Glinghammar B, Skogsberg J, Hamsten A, Ehrenborg E: PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2003, 308: 361-368. 10.1016/S0006-291X(03)01384-6.CrossRefPubMed Glinghammar B, Skogsberg J, Hamsten A, Ehrenborg E: PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2003, 308: 361-368. 10.1016/S0006-291X(03)01384-6.CrossRefPubMed
49.
go back to reference Salminen A, Kaarniranta K: Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-kappaB signaling. Cell Signal. 2009, 22: 573-577.CrossRefPubMed Salminen A, Kaarniranta K: Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-kappaB signaling. Cell Signal. 2009, 22: 573-577.CrossRefPubMed
50.
go back to reference Sun B, Karin M: NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene. 2008, 27: 6228-6244. 10.1038/onc.2008.300.CrossRefPubMed Sun B, Karin M: NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene. 2008, 27: 6228-6244. 10.1038/onc.2008.300.CrossRefPubMed
51.
go back to reference Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H, Maluccio MA: NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett. 2009, 278: 145-155. 10.1016/j.canlet.2008.12.031. Epub 2009 Mar 2020CrossRefPubMed Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H, Maluccio MA: NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett. 2009, 278: 145-155. 10.1016/j.canlet.2008.12.031. Epub 2009 Mar 2020CrossRefPubMed
52.
go back to reference Lee KY, Kim SH, Jeong EJ, Park JH, Kim YC, Sung SH: New secoisolariciresinol derivatives from Lindera obtusiloba stems and their neuroprotective activities. Planta Med. 2009, 76: 294-297.CrossRefPubMed Lee KY, Kim SH, Jeong EJ, Park JH, Kim YC, Sung SH: New secoisolariciresinol derivatives from Lindera obtusiloba stems and their neuroprotective activities. Planta Med. 2009, 76: 294-297.CrossRefPubMed
Metadata
Title
A hepatoprotective Lindera obtusiloba extract suppresses growth and attenuates insulin like growth factor-1 receptor signaling and NF-kappaB activity in human liver cancer cell lines
Authors
Christian Freise
Martin Ruehl
Ulrike Erben
Ulf Neumann
Daniel Seehofer
Ki Young Kim
Wolfram Trowitzsch-Kienast
Thorsten Stroh
Martin Zeitz
Rajan Somasundaram
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2011
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-11-39

Other articles of this Issue 1/2011

BMC Complementary Medicine and Therapies 1/2011 Go to the issue